Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases

Aim. To determine whether the serum level of NGAL can discriminate cholangiocarcinoma from benign biliary tract disease in patients. Methods. This study was performed according to a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design. A total of 50 cholangiocarcinoma and...

Descripción completa

Detalles Bibliográficos
Autores principales: Leelawat, Kawin, Narong, Siriluck, Wannaprasert, Jerasak, Leelawat, Surang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE-Hindawi Access to Research 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170848/
https://www.ncbi.nlm.nih.gov/pubmed/21994874
http://dx.doi.org/10.4061/2011/873548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170848/
https://www.ncbi.nlm.nih.gov/pubmed/21994874
http://dx.doi.org/10.4061/2011/873548

Ejemplares similares